Uploaded March 2026 | Updated November 2026, 3 days ago
This annual lecture, begun in 2016 and part of the Wednesday Afternoon Lecture Series, honors the legacy of Dr. William E. Paul. Dr. Paul was a leader of the NIH immunology community, and his career was without parallel in the field of immunology. Dr. Belkaid’s talk focuses on how the immune system does far more than fight infections—it actively shapes the body’s physiology throughout life. Her central message is that immunity is an integrative system that orchestrates interactions between tissues, microbes, metabolism, and behavior.
For more information go to oir.nih.gov/wals
This annual lecture, begun in 2016 and part of the Wednesday Afternoon Lecture Series, honors the legacy of Dr. William E. Paul. Dr. Paul was a leader of the NIH immunology community, and his career was without parallel in the field of immunology. Dr. Belkaid’s talk focuses on how the immune system does far more than fight infections—it actively shapes the body’s physiology throughout life. Her central message is that immunity is an integrative system that orchestrates interactions between tissues, microbes, metabolism, and behavior.
For more information go to oir.nih.gov/wals
![Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme
Air date: Wednesday, February 1, 2023, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture [WALS]
See https://en.wikipedia.org/wiki/Helen_Blau
For more information go to https://oir.nih.gov/wals
Author: Helen Blau, Ph.D., Stanford Medicine
Permanent link: https://videocast.nih.gov/watch=46058 Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme](https://i.ytimg.com/vi/rPVoQesTplU/mqdefault.jpg)


![Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras
Air date: Wednesday, March 8, 2023, 2PM
Description: NIH Directors WALS Lecture [WALS]
Kevan Shokat is a chemist who discovers drugs against some of the most common drivers of human cancers. He is best known for targeting a mutation that drives more than 1 in 10 lung cancers, opening up a new arena of cancer treatment discovery. The target, K-Ras, is the most common driver of cancer, and was considered “undruggable” by most cancer researchers after 40 years of failed attempts to block its function. Dr. Shokat’s discovery of a K-Ras blocker broke through this decades-old barrier and threw open the doors to a new class of cancer treatments. Lecture summary: 1. To understand the chemical, biochemical and cellular challenges to identifying a drug to target K-Ras mutant tumors 2. To learn how to discover drugs which only target oncogenes in cancer cells while sparing signaling in the rest of the body using covalent chemistry. 3. To learn about new approaches for combination therapy in cancer including re-activation of the tumor suppressor p53 and engaging the immune cells to overcome resistance to targeted therapies.
https://cancer.ucsf.edu/people/shokat.kevan
For more information go to https://oir.nih.gov/wals
Author: Kevan Shokat, Ph.D., University of California, Berkeley
Permanent link: https://videocast.nih.gov/watch=46070 Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras](https://i.ytimg.com/vi/rtR3yl5U4yk/mqdefault.jpg)






